Global Capivasertib Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Capivasertib market size was valued at US$ 749 million in 2025 and is forecast to a readjusted size of US$ 2761 million by 2032 with a CAGR of 14.4% during review period.
Capivasertib is an oral, highly selective ATP-competitive AKT kinase inhibitor that potently inhibits the activities of AKT1/2/3 isoforms, blocks the abnormal activation of the PI3K/AKT signaling pathway, and thereby inhibits the proliferation, survival, invasion and metastasis of tumor cells. The drug is mainly developed for patients with solid tumors harboring PIK3CA/AKT1/PTEN mutations. Clinically, it is mostly used in combination with endocrine therapy for HR-positive, HER2-negative advanced breast cancer, and is also under investigation in various tumor types such as prostate cancer and colorectal cancer, providing precise targeted therapeutic options for advanced cancer patients with abnormalities in specific signaling pathways.In 2025, global Capivasertib production reached approximately 1.8 million bottles.
Capivasertib has established a core position in the treatment of HR-positive, HER2-negative advanced breast cancer by virtue of its first-mover advantage as the world’s first-in-class AKT inhibitor and a clear biomarker selection strategy. By continuously expanding its pipeline to cover multiple tumor types such as prostate cancer, it has built a broad market space. Its mechanism of action, which precisely targets the PI3K/AKT pathway, aligns perfectly with the mainstream trend of precision and individualized cancer therapy, effectively filling the clinical gap for patients with endocrine resistance. The current market landscape is oligopolistic. As the only approved AKT inhibitor on the market, Capivasertib faces limited direct competition, with only a few similar drugs in late clinical stages. With gradual market access in major global regions, the popularization of companion diagnostics, and the continuous expansion of indications, the drug is rapidly penetrating from second-line breast cancer treatment to more tumor types. It boasts significant long-term commercialization potential and is expected to become a key product driving the growth of AstraZeneca’s oncology business.
This report is a detailed and comprehensive analysis for global Capivasertib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Capivasertib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Capivasertib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Capivasertib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Capivasertib, with price, sales quantity, revenue, and global market share of Capivasertib from 2021 to 2026.
Chapter 3, the Capivasertib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Capivasertib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Capivasertib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Capivasertib.
Chapter 14 and 15, to describe Capivasertib sales channel, distributors, customers, research findings and conclusion.
Capivasertib is an oral, highly selective ATP-competitive AKT kinase inhibitor that potently inhibits the activities of AKT1/2/3 isoforms, blocks the abnormal activation of the PI3K/AKT signaling pathway, and thereby inhibits the proliferation, survival, invasion and metastasis of tumor cells. The drug is mainly developed for patients with solid tumors harboring PIK3CA/AKT1/PTEN mutations. Clinically, it is mostly used in combination with endocrine therapy for HR-positive, HER2-negative advanced breast cancer, and is also under investigation in various tumor types such as prostate cancer and colorectal cancer, providing precise targeted therapeutic options for advanced cancer patients with abnormalities in specific signaling pathways.In 2025, global Capivasertib production reached approximately 1.8 million bottles.
Capivasertib has established a core position in the treatment of HR-positive, HER2-negative advanced breast cancer by virtue of its first-mover advantage as the world’s first-in-class AKT inhibitor and a clear biomarker selection strategy. By continuously expanding its pipeline to cover multiple tumor types such as prostate cancer, it has built a broad market space. Its mechanism of action, which precisely targets the PI3K/AKT pathway, aligns perfectly with the mainstream trend of precision and individualized cancer therapy, effectively filling the clinical gap for patients with endocrine resistance. The current market landscape is oligopolistic. As the only approved AKT inhibitor on the market, Capivasertib faces limited direct competition, with only a few similar drugs in late clinical stages. With gradual market access in major global regions, the popularization of companion diagnostics, and the continuous expansion of indications, the drug is rapidly penetrating from second-line breast cancer treatment to more tumor types. It boasts significant long-term commercialization potential and is expected to become a key product driving the growth of AstraZeneca’s oncology business.
This report is a detailed and comprehensive analysis for global Capivasertib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Capivasertib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capivasertib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Capivasertib
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Capivasertib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- 160 mg
- 200 mg
- Capivasertib In Combination With Fulvestrant
- Capivasertib In Combination With Letrozole
- Hospital
- Retail
- Online
- HR-Positive, HER2-Negative Advanced Breast Cancer
- Metastatic Prostate Cancer
- Advanced Colorectal Cancer
- Others
- AstraZeneca
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Capivasertib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Capivasertib, with price, sales quantity, revenue, and global market share of Capivasertib from 2021 to 2026.
Chapter 3, the Capivasertib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Capivasertib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Capivasertib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Capivasertib.
Chapter 14 and 15, to describe Capivasertib sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Capivasertib Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 160 mg
1.3.3 200 mg
1.4 Market Analysis by Combination Therapy
1.4.1 Overview: Global Capivasertib Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
1.4.2 Capivasertib In Combination With Fulvestrant
1.4.3 Capivasertib In Combination With Letrozole
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Capivasertib Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Hospital
1.5.3 Retail
1.5.4 Online
1.6 Market Analysis by Application
1.6.1 Overview: Global Capivasertib Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 HR-Positive, HER2-Negative Advanced Breast Cancer
1.6.3 Metastatic Prostate Cancer
1.6.4 Advanced Colorectal Cancer
1.6.5 Others
1.7 Global Capivasertib Market Size & Forecast
1.7.1 Global Capivasertib Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Capivasertib Sales Quantity (2021-2032)
1.7.3 Global Capivasertib Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Capivasertib Product and Services
2.1.4 AstraZeneca Capivasertib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 AstraZeneca Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CAPIVASERTIB BY MANUFACTURER
3.1 Global Capivasertib Sales Quantity by Manufacturer (2021-2026)
3.2 Global Capivasertib Revenue by Manufacturer (2021-2026)
3.3 Global Capivasertib Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Capivasertib by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Capivasertib Manufacturer Market Share in 2025
3.4.3 Top 6 Capivasertib Manufacturer Market Share in 2025
3.5 Capivasertib Market: Overall Company Footprint Analysis
3.5.1 Capivasertib Market: Region Footprint
3.5.2 Capivasertib Market: Company Product Type Footprint
3.5.3 Capivasertib Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Capivasertib Market Size by Region
4.1.1 Global Capivasertib Sales Quantity by Region (2021-2032)
4.1.2 Global Capivasertib Consumption Value by Region (2021-2032)
4.1.3 Global Capivasertib Average Price by Region (2021-2032)
4.2 North America Capivasertib Consumption Value (2021-2032)
4.3 Europe Capivasertib Consumption Value (2021-2032)
4.4 Asia-Pacific Capivasertib Consumption Value (2021-2032)
4.5 South America Capivasertib Consumption Value (2021-2032)
4.6 Middle East & Africa Capivasertib Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Capivasertib Sales Quantity by Type (2021-2032)
5.2 Global Capivasertib Consumption Value by Type (2021-2032)
5.3 Global Capivasertib Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Capivasertib Sales Quantity by Application (2021-2032)
6.2 Global Capivasertib Consumption Value by Application (2021-2032)
6.3 Global Capivasertib Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Capivasertib Sales Quantity by Type (2021-2032)
7.2 North America Capivasertib Sales Quantity by Application (2021-2032)
7.3 North America Capivasertib Market Size by Country
7.3.1 North America Capivasertib Sales Quantity by Country (2021-2032)
7.3.2 North America Capivasertib Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Capivasertib Sales Quantity by Type (2021-2032)
8.2 Europe Capivasertib Sales Quantity by Application (2021-2032)
8.3 Europe Capivasertib Market Size by Country
8.3.1 Europe Capivasertib Sales Quantity by Country (2021-2032)
8.3.2 Europe Capivasertib Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Capivasertib Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Capivasertib Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Capivasertib Market Size by Region
9.3.1 Asia-Pacific Capivasertib Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Capivasertib Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Capivasertib Sales Quantity by Type (2021-2032)
10.2 South America Capivasertib Sales Quantity by Application (2021-2032)
10.3 South America Capivasertib Market Size by Country
10.3.1 South America Capivasertib Sales Quantity by Country (2021-2032)
10.3.2 South America Capivasertib Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Capivasertib Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Capivasertib Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Capivasertib Market Size by Country
11.3.1 Middle East & Africa Capivasertib Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Capivasertib Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Capivasertib Market Drivers
12.2 Capivasertib Market Restraints
12.3 Capivasertib Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Capivasertib and Key Manufacturers
13.2 Manufacturing Costs Percentage of Capivasertib
13.3 Capivasertib Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Capivasertib Typical Distributors
14.3 Capivasertib Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Capivasertib Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 160 mg
1.3.3 200 mg
1.4 Market Analysis by Combination Therapy
1.4.1 Overview: Global Capivasertib Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
1.4.2 Capivasertib In Combination With Fulvestrant
1.4.3 Capivasertib In Combination With Letrozole
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Capivasertib Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Hospital
1.5.3 Retail
1.5.4 Online
1.6 Market Analysis by Application
1.6.1 Overview: Global Capivasertib Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 HR-Positive, HER2-Negative Advanced Breast Cancer
1.6.3 Metastatic Prostate Cancer
1.6.4 Advanced Colorectal Cancer
1.6.5 Others
1.7 Global Capivasertib Market Size & Forecast
1.7.1 Global Capivasertib Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Capivasertib Sales Quantity (2021-2032)
1.7.3 Global Capivasertib Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Capivasertib Product and Services
2.1.4 AstraZeneca Capivasertib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 AstraZeneca Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CAPIVASERTIB BY MANUFACTURER
3.1 Global Capivasertib Sales Quantity by Manufacturer (2021-2026)
3.2 Global Capivasertib Revenue by Manufacturer (2021-2026)
3.3 Global Capivasertib Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Capivasertib by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Capivasertib Manufacturer Market Share in 2025
3.4.3 Top 6 Capivasertib Manufacturer Market Share in 2025
3.5 Capivasertib Market: Overall Company Footprint Analysis
3.5.1 Capivasertib Market: Region Footprint
3.5.2 Capivasertib Market: Company Product Type Footprint
3.5.3 Capivasertib Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Capivasertib Market Size by Region
4.1.1 Global Capivasertib Sales Quantity by Region (2021-2032)
4.1.2 Global Capivasertib Consumption Value by Region (2021-2032)
4.1.3 Global Capivasertib Average Price by Region (2021-2032)
4.2 North America Capivasertib Consumption Value (2021-2032)
4.3 Europe Capivasertib Consumption Value (2021-2032)
4.4 Asia-Pacific Capivasertib Consumption Value (2021-2032)
4.5 South America Capivasertib Consumption Value (2021-2032)
4.6 Middle East & Africa Capivasertib Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Capivasertib Sales Quantity by Type (2021-2032)
5.2 Global Capivasertib Consumption Value by Type (2021-2032)
5.3 Global Capivasertib Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Capivasertib Sales Quantity by Application (2021-2032)
6.2 Global Capivasertib Consumption Value by Application (2021-2032)
6.3 Global Capivasertib Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Capivasertib Sales Quantity by Type (2021-2032)
7.2 North America Capivasertib Sales Quantity by Application (2021-2032)
7.3 North America Capivasertib Market Size by Country
7.3.1 North America Capivasertib Sales Quantity by Country (2021-2032)
7.3.2 North America Capivasertib Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Capivasertib Sales Quantity by Type (2021-2032)
8.2 Europe Capivasertib Sales Quantity by Application (2021-2032)
8.3 Europe Capivasertib Market Size by Country
8.3.1 Europe Capivasertib Sales Quantity by Country (2021-2032)
8.3.2 Europe Capivasertib Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Capivasertib Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Capivasertib Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Capivasertib Market Size by Region
9.3.1 Asia-Pacific Capivasertib Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Capivasertib Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Capivasertib Sales Quantity by Type (2021-2032)
10.2 South America Capivasertib Sales Quantity by Application (2021-2032)
10.3 South America Capivasertib Market Size by Country
10.3.1 South America Capivasertib Sales Quantity by Country (2021-2032)
10.3.2 South America Capivasertib Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Capivasertib Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Capivasertib Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Capivasertib Market Size by Country
11.3.1 Middle East & Africa Capivasertib Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Capivasertib Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Capivasertib Market Drivers
12.2 Capivasertib Market Restraints
12.3 Capivasertib Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Capivasertib and Key Manufacturers
13.2 Manufacturing Costs Percentage of Capivasertib
13.3 Capivasertib Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Capivasertib Typical Distributors
14.3 Capivasertib Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Capivasertib Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Capivasertib Consumption Value by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Table 3. Global Capivasertib Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Capivasertib Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca Capivasertib Product and Services
Table 8. AstraZeneca Capivasertib Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. AstraZeneca Recent Developments/Updates
Table 10. Global Capivasertib Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 11. Global Capivasertib Revenue by Manufacturer (2021-2026) & (USD Million)
Table 12. Global Capivasertib Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 13. Market Position of Manufacturers in Capivasertib, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 14. Head Office and Capivasertib Production Site of Key Manufacturer
Table 15. Capivasertib Market: Company Product Type Footprint
Table 16. Capivasertib Market: Company Product Application Footprint
Table 17. Capivasertib New Market Entrants and Barriers to Market Entry
Table 18. Capivasertib Mergers, Acquisition, Agreements, and Collaborations
Table 19. Global Capivasertib Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 20. Global Capivasertib Sales Quantity by Region (2021-2026) & (Units)
Table 21. Global Capivasertib Sales Quantity by Region (2027-2032) & (Units)
Table 22. Global Capivasertib Consumption Value by Region (2021-2026) & (USD Million)
Table 23. Global Capivasertib Consumption Value by Region (2027-2032) & (USD Million)
Table 24. Global Capivasertib Average Price by Region (2021-2026) & (US$/Unit)
Table 25. Global Capivasertib Average Price by Region (2027-2032) & (US$/Unit)
Table 26. Global Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 27. Global Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 28. Global Capivasertib Consumption Value by Type (2021-2026) & (USD Million)
Table 29. Global Capivasertib Consumption Value by Type (2027-2032) & (USD Million)
Table 30. Global Capivasertib Average Price by Type (2021-2026) & (US$/Unit)
Table 31. Global Capivasertib Average Price by Type (2027-2032) & (US$/Unit)
Table 32. Global Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 33. Global Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 34. Global Capivasertib Consumption Value by Application (2021-2026) & (USD Million)
Table 35. Global Capivasertib Consumption Value by Application (2027-2032) & (USD Million)
Table 36. Global Capivasertib Average Price by Application (2021-2026) & (US$/Unit)
Table 37. Global Capivasertib Average Price by Application (2027-2032) & (US$/Unit)
Table 38. North America Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 39. North America Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 40. North America Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 41. North America Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 42. North America Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 43. North America Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 44. North America Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 45. North America Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 46. Europe Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 47. Europe Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 48. Europe Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 49. Europe Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 50. Europe Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 51. Europe Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 52. Europe Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 53. Europe Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 54. Asia-Pacific Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 55. Asia-Pacific Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 56. Asia-Pacific Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 57. Asia-Pacific Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 58. Asia-Pacific Capivasertib Sales Quantity by Region (2021-2026) & (Units)
Table 59. Asia-Pacific Capivasertib Sales Quantity by Region (2027-2032) & (Units)
Table 60. Asia-Pacific Capivasertib Consumption Value by Region (2021-2026) & (USD Million)
Table 61. Asia-Pacific Capivasertib Consumption Value by Region (2027-2032) & (USD Million)
Table 62. South America Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 63. South America Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 64. South America Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 65. South America Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 66. South America Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 67. South America Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 68. South America Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 69. South America Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 70. Middle East & Africa Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 71. Middle East & Africa Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 72. Middle East & Africa Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 73. Middle East & Africa Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 74. Middle East & Africa Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 75. Middle East & Africa Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 76. Middle East & Africa Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 78. Capivasertib Raw Material
Table 79. Key Manufacturers of Capivasertib Raw Materials
Table 80. Capivasertib Typical Distributors
Table 81. Capivasertib Typical Customers
Table 1. Global Capivasertib Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Capivasertib Consumption Value by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Table 3. Global Capivasertib Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Capivasertib Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca Capivasertib Product and Services
Table 8. AstraZeneca Capivasertib Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. AstraZeneca Recent Developments/Updates
Table 10. Global Capivasertib Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 11. Global Capivasertib Revenue by Manufacturer (2021-2026) & (USD Million)
Table 12. Global Capivasertib Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 13. Market Position of Manufacturers in Capivasertib, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 14. Head Office and Capivasertib Production Site of Key Manufacturer
Table 15. Capivasertib Market: Company Product Type Footprint
Table 16. Capivasertib Market: Company Product Application Footprint
Table 17. Capivasertib New Market Entrants and Barriers to Market Entry
Table 18. Capivasertib Mergers, Acquisition, Agreements, and Collaborations
Table 19. Global Capivasertib Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 20. Global Capivasertib Sales Quantity by Region (2021-2026) & (Units)
Table 21. Global Capivasertib Sales Quantity by Region (2027-2032) & (Units)
Table 22. Global Capivasertib Consumption Value by Region (2021-2026) & (USD Million)
Table 23. Global Capivasertib Consumption Value by Region (2027-2032) & (USD Million)
Table 24. Global Capivasertib Average Price by Region (2021-2026) & (US$/Unit)
Table 25. Global Capivasertib Average Price by Region (2027-2032) & (US$/Unit)
Table 26. Global Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 27. Global Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 28. Global Capivasertib Consumption Value by Type (2021-2026) & (USD Million)
Table 29. Global Capivasertib Consumption Value by Type (2027-2032) & (USD Million)
Table 30. Global Capivasertib Average Price by Type (2021-2026) & (US$/Unit)
Table 31. Global Capivasertib Average Price by Type (2027-2032) & (US$/Unit)
Table 32. Global Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 33. Global Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 34. Global Capivasertib Consumption Value by Application (2021-2026) & (USD Million)
Table 35. Global Capivasertib Consumption Value by Application (2027-2032) & (USD Million)
Table 36. Global Capivasertib Average Price by Application (2021-2026) & (US$/Unit)
Table 37. Global Capivasertib Average Price by Application (2027-2032) & (US$/Unit)
Table 38. North America Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 39. North America Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 40. North America Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 41. North America Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 42. North America Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 43. North America Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 44. North America Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 45. North America Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 46. Europe Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 47. Europe Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 48. Europe Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 49. Europe Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 50. Europe Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 51. Europe Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 52. Europe Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 53. Europe Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 54. Asia-Pacific Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 55. Asia-Pacific Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 56. Asia-Pacific Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 57. Asia-Pacific Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 58. Asia-Pacific Capivasertib Sales Quantity by Region (2021-2026) & (Units)
Table 59. Asia-Pacific Capivasertib Sales Quantity by Region (2027-2032) & (Units)
Table 60. Asia-Pacific Capivasertib Consumption Value by Region (2021-2026) & (USD Million)
Table 61. Asia-Pacific Capivasertib Consumption Value by Region (2027-2032) & (USD Million)
Table 62. South America Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 63. South America Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 64. South America Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 65. South America Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 66. South America Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 67. South America Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 68. South America Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 69. South America Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 70. Middle East & Africa Capivasertib Sales Quantity by Type (2021-2026) & (Units)
Table 71. Middle East & Africa Capivasertib Sales Quantity by Type (2027-2032) & (Units)
Table 72. Middle East & Africa Capivasertib Sales Quantity by Application (2021-2026) & (Units)
Table 73. Middle East & Africa Capivasertib Sales Quantity by Application (2027-2032) & (Units)
Table 74. Middle East & Africa Capivasertib Sales Quantity by Country (2021-2026) & (Units)
Table 75. Middle East & Africa Capivasertib Sales Quantity by Country (2027-2032) & (Units)
Table 76. Middle East & Africa Capivasertib Consumption Value by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Capivasertib Consumption Value by Country (2027-2032) & (USD Million)
Table 78. Capivasertib Raw Material
Table 79. Key Manufacturers of Capivasertib Raw Materials
Table 80. Capivasertib Typical Distributors
Table 81. Capivasertib Typical Customers
LIST OF FIGURES
Figure 1. Capivasertib Picture
Figure 2. Global Capivasertib Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Capivasertib Revenue Market Share by Type in 2025
Figure 4. 160 mg Examples
Figure 5. 200 mg Examples
Figure 6. Global Capivasertib Revenue by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Capivasertib Revenue Market Share by Combination Therapy in 2025
Figure 8. Capivasertib In Combination With Fulvestrant Examples
Figure 9. Capivasertib In Combination With Letrozole Examples
Figure 10. Global Capivasertib Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Capivasertib Revenue Market Share by Sales Channels in 2025
Figure 12. Hospital Examples
Figure 13. Retail Examples
Figure 14. Online Examples
Figure 15. Global Capivasertib Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Capivasertib Revenue Market Share by Application in 2025
Figure 17. HR-Positive, HER2-Negative Advanced Breast Cancer Examples
Figure 18. Metastatic Prostate Cancer Examples
Figure 19. Advanced Colorectal Cancer Examples
Figure 20. Others Examples
Figure 21. Global Capivasertib Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Capivasertib Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Capivasertib Sales Quantity (2021-2032) & (Units)
Figure 24. Global Capivasertib Price (2021-2032) & (US$/Unit)
Figure 25. Global Capivasertib Sales Quantity Market Share by Manufacturer in 2025
Figure 26. Global Capivasertib Revenue Market Share by Manufacturer in 2025
Figure 27. Producer Shipments of Capivasertib by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 28. Top 3 Capivasertib Manufacturer (Revenue) Market Share in 2025
Figure 29. Top 6 Capivasertib Manufacturer (Revenue) Market Share in 2025
Figure 30. Global Capivasertib Sales Quantity Market Share by Region (2021-2032)
Figure 31. Global Capivasertib Consumption Value Market Share by Region (2021-2032)
Figure 32. North America Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 33. Europe Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 34. Asia-Pacific Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 35. South America Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 36. Middle East & Africa Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 37. Global Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 38. Global Capivasertib Consumption Value Market Share by Type (2021-2032)
Figure 39. Global Capivasertib Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. Global Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 41. Global Capivasertib Revenue Market Share by Application (2021-2032)
Figure 42. Global Capivasertib Average Price by Application (2021-2032) & (US$/Unit)
Figure 43. North America Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 44. North America Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 45. North America Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 46. North America Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 51. Europe Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 52. Europe Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 53. Europe Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 55. France Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Capivasertib Sales Quantity Market Share by Region (2021-2032)
Figure 62. Asia-Pacific Capivasertib Consumption Value Market Share by Region (2021-2032)
Figure 63. China Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 66. India Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 70. South America Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 71. South America Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 72. South America Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 73. Brazil Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 74. Argentina Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 75. Middle East & Africa Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 76. Middle East & Africa Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 77. Middle East & Africa Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 78. Middle East & Africa Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 79. Turkey Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 80. Egypt Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 81. Saudi Arabia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 82. South Africa Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 83. Capivasertib Market Drivers
Figure 84. Capivasertib Market Restraints
Figure 85. Capivasertib Market Trends
Figure 86. Porters Five Forces Analysis
Figure 87. Manufacturing Cost Structure Analysis of Capivasertib in 2025
Figure 88. Manufacturing Process Analysis of Capivasertib
Figure 89. Capivasertib Industrial Chain
Figure 90. Sales Channel: Direct to End-User vs Distributors
Figure 91. Direct Channel Pros & Cons
Figure 92. Indirect Channel Pros & Cons
Figure 93. Methodology
Figure 94. Research Process and Data Source
Figure 1. Capivasertib Picture
Figure 2. Global Capivasertib Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Capivasertib Revenue Market Share by Type in 2025
Figure 4. 160 mg Examples
Figure 5. 200 mg Examples
Figure 6. Global Capivasertib Revenue by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Capivasertib Revenue Market Share by Combination Therapy in 2025
Figure 8. Capivasertib In Combination With Fulvestrant Examples
Figure 9. Capivasertib In Combination With Letrozole Examples
Figure 10. Global Capivasertib Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Capivasertib Revenue Market Share by Sales Channels in 2025
Figure 12. Hospital Examples
Figure 13. Retail Examples
Figure 14. Online Examples
Figure 15. Global Capivasertib Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Capivasertib Revenue Market Share by Application in 2025
Figure 17. HR-Positive, HER2-Negative Advanced Breast Cancer Examples
Figure 18. Metastatic Prostate Cancer Examples
Figure 19. Advanced Colorectal Cancer Examples
Figure 20. Others Examples
Figure 21. Global Capivasertib Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Capivasertib Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Capivasertib Sales Quantity (2021-2032) & (Units)
Figure 24. Global Capivasertib Price (2021-2032) & (US$/Unit)
Figure 25. Global Capivasertib Sales Quantity Market Share by Manufacturer in 2025
Figure 26. Global Capivasertib Revenue Market Share by Manufacturer in 2025
Figure 27. Producer Shipments of Capivasertib by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 28. Top 3 Capivasertib Manufacturer (Revenue) Market Share in 2025
Figure 29. Top 6 Capivasertib Manufacturer (Revenue) Market Share in 2025
Figure 30. Global Capivasertib Sales Quantity Market Share by Region (2021-2032)
Figure 31. Global Capivasertib Consumption Value Market Share by Region (2021-2032)
Figure 32. North America Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 33. Europe Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 34. Asia-Pacific Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 35. South America Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 36. Middle East & Africa Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 37. Global Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 38. Global Capivasertib Consumption Value Market Share by Type (2021-2032)
Figure 39. Global Capivasertib Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. Global Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 41. Global Capivasertib Revenue Market Share by Application (2021-2032)
Figure 42. Global Capivasertib Average Price by Application (2021-2032) & (US$/Unit)
Figure 43. North America Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 44. North America Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 45. North America Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 46. North America Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 51. Europe Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 52. Europe Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 53. Europe Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 55. France Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Capivasertib Sales Quantity Market Share by Region (2021-2032)
Figure 62. Asia-Pacific Capivasertib Consumption Value Market Share by Region (2021-2032)
Figure 63. China Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 66. India Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 70. South America Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 71. South America Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 72. South America Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 73. Brazil Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 74. Argentina Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 75. Middle East & Africa Capivasertib Sales Quantity Market Share by Type (2021-2032)
Figure 76. Middle East & Africa Capivasertib Sales Quantity Market Share by Application (2021-2032)
Figure 77. Middle East & Africa Capivasertib Sales Quantity Market Share by Country (2021-2032)
Figure 78. Middle East & Africa Capivasertib Consumption Value Market Share by Country (2021-2032)
Figure 79. Turkey Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 80. Egypt Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 81. Saudi Arabia Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 82. South Africa Capivasertib Consumption Value (2021-2032) & (USD Million)
Figure 83. Capivasertib Market Drivers
Figure 84. Capivasertib Market Restraints
Figure 85. Capivasertib Market Trends
Figure 86. Porters Five Forces Analysis
Figure 87. Manufacturing Cost Structure Analysis of Capivasertib in 2025
Figure 88. Manufacturing Process Analysis of Capivasertib
Figure 89. Capivasertib Industrial Chain
Figure 90. Sales Channel: Direct to End-User vs Distributors
Figure 91. Direct Channel Pros & Cons
Figure 92. Indirect Channel Pros & Cons
Figure 93. Methodology
Figure 94. Research Process and Data Source
